Litcius/Paper detail

Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial

Marion Leboyer, Marianne Foiselle, Nicolas Tchitchek, Ryad Tamouza, Roberta Lorenzon, Jean‐Romain Richard, Raphaele Arrouasse, Philippe Le Corvoisier, Katia Le Dudal, Éric Vicaut, Pierre Ellul, Michèlle Rosenzwajg, David Klatzmann

2024Brain Behavior and Immunity11 citationsDOI

Topics & Concepts

Depression (economics)Double blindInflammationPlaceboMedicineBipolar disorderInternal medicineImmune systemInterleukinImmunologyCytokineLithium (medication)PathologyAlternative medicineMacroeconomicsEconomicsBipolar Disorder and TreatmentTryptophan and brain disordersAdolescent and Pediatric Healthcare
Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial | Litcius